chartexchange

SELLAS Stock Triples on Cancer Vaccine Cutting Death Risk by 41% in Pivotal Leukemia Trial,

Benzinga | Nov 17, 2026 10:09 AM EST

SELLAS Life Sciences Group Inc. (NASDAQ:SLS) skyrocketed to a 52-week high on Tuesday with a session volume of a massive 57.567 million compared to an average volume of 6.897 million, according to Benzinga Pro data .



The company released positive topline results from its pivotal randomized Phase 3 REGAL trial evaluating galinpepimut-S (GPS), an immunotherapeutic cancer vaccine for acute myeloid leukemia (AML).



The late-stage biopharmaceutical company confirmed that the study met its primary endpoint of overall survival .



Phase 3 REGAL Trial Survival Results



The trial evaluated GPS as maintenance monotherapy against investigator’s choice of best available treatment.



GPS delivered a statistically significant and clinically meaningful overall survival improvement, reducing death risk by 41% with a hazard ratio of 0.59 and a two-sided p-value of 0.035.








Read Also:

When Revolution Medicines' FDA Win Lifts Other Boats: SELLAS Life Sciences Stock Surges







Patients receiving GPS achieved a median overall survival of 24.0 months versus 14.7 months for best available treatment .



The study enrolled AML patients who reached a second or later complete remission, or complete remission with insufficient platelet recovery, after second- or later-line salvage therapy and were ineligible for or unable to undergo allogeneic stem cell transplantation.



Pre-specified data from 80 deaths triggered this topline analysis under the statistical analysis plan.



Safety Profile And Vaccine Mechanism



Patients generally tolerated GPS well, demonstrating a safety profile consistent with prior clinical experience and no new safety signals.



SELLAS licensed GPS from Memorial Sloan Kettering Cancer Center as an off-the-shelf vaccine targeting WT1, a protein expressed across a broad range of blood cancers and solid tumors.



GPS combines four WT1-derived peptides to stimulate CD4+ and CD8+ T-cell responses across multiple HLA types, prolonging remission and survival by targeting residual cancer cells.



Regulatory Strategy And Next Steps



SELLAS now plans to meet with the U.S. Food and Drug Administration to discuss an accelerated filing strategy and prepare a Biologics License Application submission for the first half of 2027.



SLS Price Action: SELLAS Life Sciences Gr shares were up 183.13% at $21.14 at the time of publication on Tuesday. The stock is trading at a new 52-week high, according to Benzinga Pro data .








Read Also:

Paysafe Expands Into Branded Digital Wallets







Image via Shutterstock/ Yomal2233

Read original article